Editas Medicine (EDIT) vs Eikon Therapeutics (EIKN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Eikon Therapeutics is the larger company by market cap ($256.8 million vs $253.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EDIT | EIKN |
|---|---|---|
| Share price | $1.64 | $4.74 |
| Market cap | $253.12M | $256.84M |
| 1-day change | -4.09% | -0.42% |
| YTD return | -20.00% | — |
| 1-year return | -32.23% | — |
| 5-year return | -94.93% | — |
| EPS (TTM) | $-0.54 | $-7.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $40.52M | — |
| Revenue growth (YoY) | +25.39% | — |
| Net income (latest FY) | $-160.06M | — |
| Operating margin | -394.89% | — |
| Net margin | -395.01% | — |
| 52-week high | $3.94 | $17.40 |
| 52-week low | $1.63 | $4.72 |
| Distance from 52-week high | -58.38% | -72.76% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +271.95% | +406.33% |
| Average volume | 2.63M | 560.40K |
| Shares outstanding | 154.34M | 54.19M |
| Employees | 87 | 384 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Editas Medicine
EDIT stock →Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 87 employees
About Eikon Therapeutics
EIKN stock →Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 384 employees
EDIT vs EIKN FAQ
Which is bigger, Editas Medicine or Eikon Therapeutics?
Eikon Therapeutics (EIKN) is larger, with a market capitalization of $256.84M compared with $253.12M for Editas Medicine (EDIT).
Are Editas Medicine and Eikon Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.